PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2019
LYON, France , April 02, 2019 (GLOBE NEWSWIRE) --                                                                                 Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN
View HTML
Toggle Summary ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting
Results support the potential for combination of erymethionase with checkpoint inhibition LYON, France and CAMBRIDGE, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F
LYON, France , March 29, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2018 “ Document de
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2019
LYON, France , March 12, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for Full Year 2018
Conference call and webcast on Tuesday, March 12 th  at 1:30 pm CET / 8:30 am EDT TRYbeCA1, a pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, now actively enrolling patients TRYbeCA2, a proof of concept Phase 2 trial in triple-negative breast cancer, open for patient enrolment
View HTML
Toggle Summary ERYTECH Presents Findings at European Red Cell Research Society Meeting
LYON, France and CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that an oral presentation
View HTML
Toggle Summary ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting
LYON, France and CAMBRIDGE, Mass. , March 08, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that Gil Beyen , the
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2018 Conference Call and Business Update
LYON, France , March 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2019
LYON, France , Feb. 06, 2019 (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the
View HTML
Toggle Summary ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
LYON, France and CAMBRIDGE, Mass. , Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled
View HTML
Top